Cytochroma and aOva Tech enter CKD accord

US drugmaker Cytochroma and aOvaTechnologies have entered into a license and supply agreement to co-develop and commercialize products directed at treating and preventing hyperphosphatemia in patients with chronic kidney disease.

Under the terms of the deal, Cytochroma gains exclusive worldwide rights to aOvaTech's proprietary technology for use in human health care. In return, aOvaTech will receive an up front license fee and royalties on the sale of products covered by the license. Further financial terms were not disclosed. aOvaTech will also supply Cytochroma with material for development and commercialization.

The firm says that, despite the availability of new phosphorus-binding agents, it remains a challenge for many ESRD patients to maintain their serum phosphorus levels within targeted ranges. According to the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease, Guideline 3, fewer than 30% of dialysis patients are able to maintain serum phosphorus levels in the target ranges.